You’ve likely heard of the pharma patent cliff. But upcoming drug patent expiration dates are also threatening another sector: university technology transfer offices.
The University of Minnesota, which has spent years resuscitating its tech transfer prowess, is now among the institutions facing a patent cliff that will dry up revenue from commercialized research. Most of its tech transfer revenue over the last decade has come from the patents related to the Ziagen AIDS drug that will fully expire in 2013.
The tech transfer office will lose $6 million to $7 million annually after that drug patent expiration date passes, according to a panel of three experts commissioned to review the university’s Office for Technology Commercialization.
To read the full, original article click on this link: Minnesota tech transfer faces a new challenge: the patent cliff
Author:Arundhati Parmar
